|
ChemicalBook Optimization Suppliers |
| 名前: |
Alfa Chemistry |
| 電話番号: |
+1-5166625404; |
| 電子メール: |
Info@alfa-chemistry.com |
|
| | 4,6,6aα,7,8,12bβ-ヘキサヒドロ-7-メチルインドロ[4,3-ab]フェナントリジン 製品概要 |
| 化学名: | 4,6,6aα,7,8,12bβ-ヘキサヒドロ-7-メチルインドロ[4,3-ab]フェナントリジン | | 英語化学名: | CY 208-243 | | 别名: | (-)-(6AR,12BR)-4,6,6A,7,8,12B-HEXAHYDRO-7-METHYLINDOLO[4,3-A]PHENANTHRIDIN;(6aR)-4,6,6aα,7,8,12bβ-Hexahydro-7-methylindolo[4,3-ab]phenanthridine;(6aR,12bβ)-4,6,6a,7,8,12b-Hexahydro-7-methylindolo[4,3-ab]phenanthridine;(6aα,12bβ)-4,6,6a,7,8,12b-Hexahydro-7-methylindolo[4,3-ab]phenanthridine;[6aR,12bR,(-)]-4,6,6a,7,8,12b-Hexahydro-7-methylindolo[4,3-ab]phenanthridine;(-)-(6aR,12bR)-4,6,6a,7,8,12β-Hexahydro-7-methylindolo[4,3-a]phenanthridin;CY 208-243;Indolo[4,3-ab]phenanthridine, 4,6,6a,7,8,12b-hexahydro-7-methyl-, (6aR,12bR)- | | CAS番号: | 100999-26-6 | | 分子式: | C19H18N2 | | 分子量: | 274.36 | | EINECS: | | | カテゴリ情報: | Dopamine receptor | | Mol File: | 100999-26-6.mol | ![4,6,6aα,7,8,12bβ-ヘキサヒドロ-7-メチルインドロ[4,3-ab]フェナントリジン](CAS/GIF/100999-26-6.gif) |
| | 4,6,6aα,7,8,12bβ-ヘキサヒドロ-7-メチルインドロ[4,3-ab]フェナントリジン 物理性質 |
| 沸点 | 466.5±33.0 °C(Predicted) | | 比重(密度) | 1.225±0.06 g/cm3(Predicted) | | 貯蔵温度 | Store at RT | | 溶解性 | Soluble to 100 mM in DMSO | | 外見 | Powder | | 酸解離定数(Pka) | 17.40±0.20(Predicted) | | 色 | White to off-white |
| | 4,6,6aα,7,8,12bβ-ヘキサヒドロ-7-メチルインドロ[4,3-ab]フェナントリジン Usage And Synthesis |
| 使用 | CY 208-243 is a selective D1DR receptor agonist. | | 定義 | ChEBI: LSM-3788 is a member of phenanthridines. | | 生物活性 | Centrally active dopamine D 1 receptor agonist, selective over D 2 receptor sites. Stimulates adenylate cyclase in rat striatal homogenates with an EC 50 of 125 nM. Unlike SKF 38393 ((?-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol hydrobromide ), it exerts anti-Parkinsonian activity in animal models. | | in vivo | Pretreatment with CY 208-243 (2.5 mg/kg; s.c.) prevents the increase of DA release and metabolism induced by the D-1 antagonist, SCH 23390 (0.05 mg/kg; s.c.)[1].
| Animal Model: | Male Sprague-Dawley rats (180-200 g)[1] | | Dosage: | 2.5 mg/kg | | Administration: | Subcutaneous | | Result: | Prevented the increase of DA release and metabolism induced by the D-1 antagonist. |
| | IC 50 | D1 Receptor | | 貯蔵 | Store at RT |
|